Evolving Considerations in the Treatment and Management of Advanced Non-Small Cell Lung Cancer (NSCLC)

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2023 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2023 to August 1, 2024
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
Merck Sharp & Dohme LLC and Sanofi

Description:
Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers, and during 2023, it is expected that there will be approximately 238,340 new cases of lung cancer. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there will be an estimated 127,070 deaths from lung cancer in 2023, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. As more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets, especially around KRAS mutation–positive NSCLC. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer. Healthcare professionals (HCPs) need to be aware of information regarding tumor-specific diagnosis, expanding treatment options, and supporting data to maximize the care of their patients. Additionally, more agents have recently been approved for patients with KRAS mutation–positive NSCLC and these options have shown the ability to help increase prognosis and quality of life in NSCLC patients. With so many effective treatment options becoming available, it is critical to inform physician medical directors, oncologists and nurses about these agents, and strategies to effectively manage NSCLC patients.

Upon completion of this activity, participants will be able to:

  • Examine the clinical and economic burden of non-small cell lung cancer (NSCLC) in terms of relative survival, mortality, drug utilization, adverse event management, and hospitalizations

  • Determine optimal approaches for biomarker testing in NSCLC, including detection and assessment of CEACAM5 expression

  • Describe key efficacy and safety outcomes from recent clinical trials that evaluated new and emerging therapies, including antibody-drug conjugates and immune checkpoint inhibitors, for advanced NSCLC

  • Evaluate the role of CEACAM5 in NSCLC and the potential role of anti-CEACAM5 antibody-drug conjugates

  • Analyze evidence-based collaborative strategies to identify, monitor, and manage adverse events associated with antibody-drug conjugates and immunotherapies for NSCLC

  • Explore managed care considerations to facilitate optimal use of current and emerging therapies, including antibody-drug conjugates and immunotherapies, in advanced NSCLC

     

Faculty: Mark A. Socinski, MD
Executive Medical Director
AdventHealth Cancer Institute

Disclosure:

(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Socinski has served as a consultant for Genentech and Novartis. He has served as a speaker for AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Genentech, Lilly, and Novartis. He has received grant/research support from AstraZeneca, Roche, and Takeda. His presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
Merck Sharp & Dohme LLC and Sanofi


NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue